ePlaza Magazine
Submit news for free

Dr Reddy’s gets 4 observations from USFDA for Telangana plant

NEW DELHI: Drug major Dr Reddy’s Laboratories today said the US health regulator had issued four observations after inspecting its active pharmaceutical ingredients (API) facility in Telangana.

“The audit of our API Hyderabad plant 1 at Jinnaram Mandal, Medak district, Telangana, by the USFDA has been completed today. We have been issued a Form 483 with four observations which will be addressed comprehensively within stipulated time,” Dr Reddy’s said in a regulatory filing.

As per the USFDA, a Form 483 is issued to a firm’s management at the conclusion of an inspection when investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

It notifies the company’s management of objectionable conditions.

Dr Reddy’s shares were trading 1.71 per cent down at Rs 2145.95 on the BSE.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More